Kelly Lynn Summers

Kelly Lynn Summers

Auto-generated profile, based on publicly available information

Kelly Lynn Summers

Molecular and Environmental Sciences Group, Department of Geological Sciences, University of Saskatchewan, 114 Science Place, Saskatoon, Saskatchewan S7N 5E2, Canada

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2017 in Biochemistry
Verified
Journal Article
Closed access
KSKelly L. Summers
Kelly L. Summers
NFNicholas Fimognari
Nicholas Fimognari
AHAshley Hollings
Ashley Hollings
MKMitchell Kiernan
Mitchell Kiernan
VLVirginie Lam
Virginie Lam
MHMark Hackett
Mark Hackett

7 August 2012 in Biochemistry
Verified
Journal Article
Closed access
DSDuncan E. K. Sutherland
Duncan E. K. Sutherland
KSKelly L. Summers
Kelly L. Summers
Martin StillmanMartin Stillman
Martin Stillman

23 April 2019 in Inorganic Chemistry
Verified
Journal Article
Closed access
KSKelly L. Summers
Kelly L. Summers
KSKevin M. Schilling
Kevin M. Schilling
GRGraham Roseman
Graham Roseman
KMKate A. Markham
Kate A. Markham
NDNatalia V. Dolgova
Natalia V. Dolgova
GGGraham N. George
Graham N. George

28 March 2019 in Mini-Reviews in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
KSKelly Lynn Summers
Kelly Lynn Summers
Malaria is a potentially life-threatening disease, affecting approx. 214 million people worldwide. Malaria is caused by a protozoan, Plasmodium falciparum, which is transmitted through the Anopheles mosquito. Malaria treatment is becoming more challenging due to rising resistance against the antimalarial drug, chloroquine. Novel compounds that target aspects of parasite development are being explored in attempts to overcome this wide-spread problem. Anti-malarial drugs target specific aspects of parasite growth and development within the human host. One of the most effective targets is the inhibition of hematin formation, either through inhibition of cysteine proteases or through iron chelation. Metal-thiosemicarbazone (TSC) complexes have been tested for antimalarial efficacy against drug-sensitive and drug-resistant strains of P. falciparum. An array of TSC complexes with numerous transition metals, including ruthenium, palladium, and gold has displayed antiplasmodial activity. Au(I)- and Pd(II)-TSC complexes displayed the greatest potency; 4-amino-7-chloroquine moieties were also found to improve antiplasmodial activity of TSCs. Although promising metal-TSC drug candidates have been tested against laboratory strains of P. falciparum, problems arise when attempting to compare between studies. Future work should strive to completely characterize synthesized metal-TSC structures and assess antiplasmodial potency against several drug-sensitive and drugresistant strains. Future studies need to precisely determine IC50 values for antimalarial drugs, chloroquine and ferroquine, to establish accurate standard values. This will make future comparisons across studies more feasible and potentially help reveal structure-function relationships. Investigations that attempt to link drug structures or properties to antiplasmodial mechanism(s) of action will aid in the design of antimalarial drugs that may combat rising drug resistance.

26 September 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
EKEkaterina Kabin
Ekaterina Kabin
YDYixuan Dong
Yixuan Dong
SRShubhrajit Roy
Shubhrajit Roy
JSJulia Smirnova
Julia Smirnova
JSJoshua Smith
Joshua Smith
SLSvetlana Lutsenko
Svetlana Lutsenko
α-lipoic acid (LA) is an essential cofactor for mitochondrial dehydrogenases and is required for cell growth, metabolic fuel production, and antioxidant defense. In vitro, LA binds copper (Cu) with high affinity and as an endogenous membrane permeable metabolite could be advantageous in mitigating the consequences of Cu overload in human diseases. We tested this hypothesis in 3T3-L1 preadipocytes with inactivated Cu transporter Atp7a; these cells accumulate Cu and show morphologic changes and mitochondria impairment. Treatment with LA corrected the morphology ofAtp7a−/−cells similar to the Cu chelator bathocuproinedisulfonate (BCS) and improved mitochondria function; however, the mechanisms of LA and BCS action were different. Unlike BCS, LA did not decrease intracellular Cu but instead increased selenium levels that were low inAtp7a−/−cells. Proteome analysis confirmed distinct cell responses to these compounds and identified upregulation of selenoproteins as the major effect of LA on preadipocytes. Upregulation of selenoproteins was associated with an improved GSH:GSSG ratio in cellular compartments, which was lowered by elevated Cu, and reversal of protein oxidation. Thus, LA diminishes toxic effects of elevated Cu by improving cellular redox environment. We also show that selenium levels are decreased in tissues of a Wilson disease animal model, especially in the liver, making LA an attractive candidate for supplemental treatment of this disease.

23 November 2020 in Inorganic Chemistry
Verified
Journal Article
Closed access
KSKelly L. Summers
Kelly L. Summers
GRGraham P. Roseman
Graham P. Roseman
GSGeorge J. Sopasis
George J. Sopasis
GMGlenn L. Millhauser
Glenn L. Millhauser
HHHugh Harris
Hugh Harris
GGGraham N. George
Graham N. George